B. Metzler seel. Sohn & Co. AG Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• B. Metzler seel. Sohn & Co. AG increased its Regeneron position by 37.5% in the second quarter, adding 1,220 shares for a total of 4,472 shares valued at approximately $2.79 million. Institutional investors collectively own 83.31% of the company.
• Regeneron reported strong quarterly results, with earnings of $14.29 per share and revenue of $4.29 billion, exceeding analyst expectations; revenue rose 16.7% year over year. The company also declared a quarterly dividend of $0.94 per share.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $800.36, although insiders sold $3.43 million of stock over the past 90 days and the company faces litigation-related risks tied to its Fianlimab-Libtayo trial.

B. Metzler seel. Sohn & Co. AG grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,472 shares of the biopharmaceutical company's stock after purchasing an additional 1,220 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Regeneron Pharmaceuticals were worth $2,788,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Insigneo Advisory Services LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company's stock worth $343,000 after purchasing an additional 13 shares during the last quarter. Arjuna Capital lifted its position in Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock worth $353,000 after buying an additional 14 shares in the last quarter. Guardian Wealth Advisors LLC NC lifted its position in Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company's stock worth $342,000 after buying an additional 14 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 15 shares during the last quarter. Finally, MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the business's stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president directly owned 12,003 shares of the company's stock, valued at $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,146 shares of company stock worth $3,432,488 over the last ninety days. Insiders own 6.97% of the company's stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Recent commentary continues to view Regeneron as a potentially attractive long-term biotech investment, supported by its established commercial portfolio, development pipeline and strong financial profile. However, the comparison with Vertex reportedly gives Vertex the clearer near-term investment edge. Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
• Neutral Sentiment: Regeneron’s Phase 1/2 study combining cemiplimab with SNS-101 has been completed, providing a pipeline milestone, although no efficacy or regulatory results were released. Cemiplimab Combination Trial Completion
• Negative Sentiment: Several law firms are recruiting investors for a securities class action alleging that Regeneron and certain executives misled shareholders about the viability and risks of the Phase 3 Fianlimab-Libtayo trial, including its protocol change and failure to meet the primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates potential reputational, legal and financial risks. Regeneron Class Action Deadline Alert
• Negative Sentiment: Director Kathryn Guarini sold 400 shares for $340,000, while EVP Marion McCourt sold 2,346 shares for approximately $2.0 million. All sales were made under pre-arranged Rule 10b5-1 plans, reducing their value as discretionary bearish signals, but the transactions may weigh on sentiment near recent highs. SEC Insider Transaction Filing

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on REGN. Royal Bank Of Canada raised their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. Benchmark raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Finally, Leerink Partners lifted their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research note on Monday, August 17th. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $800.36.

Regeneron Pharmaceuticals Stock Down 1.9%

Shares of REGN opened at $827.72 on Friday. The company's 50-day simple moving average is $738.29 and its 200-day simple moving average is $720.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $859.34. The stock has a market capitalization of $85.22 billion, a PE ratio of 20.46, a P/E/G ratio of 1.65 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same quarter in the previous year, the business posted $12.81 earnings per share. The business's quarterly revenue was up 16.7% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source